UK launches medical cannabis pilot

A pilot to assess the effectiveness of medical cannabis has been launched in the UK. The TWENT21 project aims to enrol 20,000 patients by 2021 and will assess efficacy, safety and Quality Adjusted Life Years (QALY) attributable to medical cannabis. The pilot will investigate the use of medical cannabis where previous interventions have failed to treat chronic pain, post-traumatic stress disorder (PTSD), multiple sclerosis, Tourette’s syndrome and substance use disorders. The pilot will also investigate the efficacy of medical cannabis in prison populations as a harm reduction strategy.